For the majority of PC patients, monotherapy treatment using PD-1 or CTLA-4 blockade has failed to produce any objective response, since some of the subjects experienced grade 3 or 4 adverse events related to treatment, and there were no responders [143,144]. The gene discussed is CTLA4; the disease is pachyonychia congenita.